FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin  via  SHP dependent inhibition of Bcl-xL expression

Wei Wang; Ming Zhan; Qi Li; Wei Chen; Huiling Chu; Qihong Huang; Zhaoyuan Hou; Mohan Man; Jian Wang

doi:10.18632/oncotarget.8964

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression

Wei Wang _, Ming Zhan, Qi Li, Wei Chen, Huiling Chu, Qihong Huang, Zhaoyuan Hou, Mohan Man and Jian Wang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:34617-34629. https://doi.org/10.18632/oncotarget.8964

Metrics: PDF 2440 views | HTML 2780 views | ?

Abstract

Wei Wang1, Ming Zhan1, Qi Li2, Wei Chen1, Huiling Chu2, Qihong Huang3, Zhaoyuan Hou2, Mohan Man2, Jian Wang1

1Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China

2Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Institutes of Medical Sciences, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China

3The Wistar Institute, Philadelphia, PA 19104, USA

Correspondence to:

Jian Wang, e-mail: [email protected]

Keywords: farnesoid X receptor, cisplatin, small heterodimer partner, signal transducer and activators of transcription 3, biliary tract cancer

Received: December 06, 2015 Accepted: April 11, 2016 Published: April 25, 2016

ABSTRACT

Chemoresistance is common in patients with biliary tract cancer (BTC) including gallbladder cancer (GBC) and cholangiocarcinoma (CC). Therefore, it is necessary to identify effective chemotherapeutic agents for BTC. In the present study, we for the first time tested the effect of farnesoid X receptor (FXR) agonists GW4064 and CDCA (chenodeoxycholic acid) in combination with cisplatin (CDDP) on increasing the chemosensitivity in BTC. Our results show that co-treatment of CDDP with FXR agonists remarkably enhance chemosensitivity of BTC cells. Mechanistically, we found that activation of FXR induced expression of small heterodimer partner (SHP), which in turn inhibited signal transducer and activator of transcription 3 (STAT3) phosphorylation and resulted in down-regulation of Bcl-xL expression in BTC cells, leading to increased susceptibility to CDDP. Moreover, the experiments on tumor-bearing mice showed that GW4064/CDDP co-treatment inhibited the tumor growth in vivo by up-regulating SHP expression and down-regulating STAT3 phosphorylation. These results suggest CDDP in combination with FXR agonists could be a potential new therapeutic strategy for BTC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8964

Publication Alerts

Research Papers:

FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression

Abstract